

Under the Paperwork Reduction Act of 1994, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.: 2003_1709  First Named Inventor : Eric COSSEMENT et al.  Title: ENANTIOMERS OF 1-[(4-CHLOROPHENYL)PHENYLMETHYL)-4-[(4-METHYLPHENYL)SULF ONYL]PIPERAZINE  Express Mail Label No.:
---	---

<b>APPLICATION ELEMENTS</b>  <i>See MPEP chapter 600 concerning utility patent application contents.</i>	ADDRESS TO: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450
--	--

1. <input checked="" type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i>  2. <input type="checkbox"/> Small Entity Status is hereby asserted.  3. <input checked="" type="checkbox"/> Specification <span style="float: right;">[Total Pages: 36]</span> <i>(preferred arrangement set forth below)</i> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Sequence Listing, a table, or a computer program listing appendix.  - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings <i>(if filed)</i> - Detailed Description - Claim(s) - Abstract of the Disclosure  4. <input type="checkbox"/> Drawing(s) (35 USC 113) <span style="float: right;">[Total Sheets: ]</span>  5. <input checked="" type="checkbox"/> Oath or Declaration <span style="float: right;">[Total Pages : 2]</span> a.1. <input type="checkbox"/> Newly executed (original or copy) a.2. <input type="checkbox"/> Unexecuted b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i>  i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).  6. <input type="checkbox"/> Application Data Sheet (see 37 CFR 1.76)	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or computer program <i>(Appendix)</i>  8. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i> a. <input type="checkbox"/> Computer Readable Form b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> Paper c. <input type="checkbox"/> The paper and computer readable copies are identical  <b>ACCOMPANYING APPLICATION PARTS</b>  9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney 11. <input type="checkbox"/> English Translation Document <i>(if applicable)</i> 12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 13. <input checked="" type="checkbox"/> Preliminary Amendment 14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 16. <input type="checkbox"/> Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. <input checked="" type="checkbox"/> Other Change of Address
--	---


18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below, and in a preliminary amendment, or in an Application Data Sheet :

☒ Continuation      ☐ Divisional      ☐ Continuation-in-part (CIP)      of prior application No. 10/385,522, filed March 12, 2003

Prior Application Information: Examiner Emily B. Bernhardt      Group Art Unit 1624

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference therein. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS           <div style="text-align: center;"> <b>CUSTOMER NO.</b>  <b>000513</b> </div>	<div style="text-align: center;">         By: Michael R. Davis        Registration No. 25,134 for        John T. Miller        Registration No. 21,120         WENDEROTH, LIND &amp; PONACK, L.L.P.        2033 "K" Street, N.W., Suite 800        Washington, D.C. 20006-1021        Phone: (202) 721-8200        Fax: (202) 721-8250         December 2, 2003     </div>
---	--

THE COMMISSIONER IS AUTHORIZED  
 TO CHARGE ANY DEFICIENCY IN THE  
 FEE FOR THIS PATENT TO DEPOSIT  
 ACCOUNT NO. 23-0975.

22264 U.S. PTO 10/724640

120203

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Eric COSSEMENT et al. :  
Serial No. NEW : **Attn: APPLICATION BRANCH**  
Filed December 2, 2003 : Attorney Docket No. 2003-1709  
ENANTIOMERS OF 1-[(4-CHLOROPHENYL)  
PHENYLMETHYL]-4-[(4-METHYLPHENYL)  
SULFONYL]PIPERAZINE :  
(Rule 1.53(b) Continuation of Serial No.  
10/385,522, Filed March 12, 2003)

**PATENT OFFICE FEE TRANSMITTAL FORM**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

Sir:

Attached hereto is a check in the amount of \$856.00 to cover Patent Office fees relating to filing the following attached papers:

Rule 53(b) Continuation application ..... \$770.00  
Additional Claims Fee:  
Independent ..... \$ 86.00


A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

*The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.*

Respectfully submitted,

Eric COSSEMENT et al.

By:

  
Michael R. Davis  
Registration No. 25,134 for  
John T. Miller  
Registration No. 21,120  
Attorney for Applicants

JTM/pth  
WENDEROTH, LIND & PONACK, L.L.P.  
2033 K St., N.W., Suite 800  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
December 2, 2003

[Check No. 58986]

2003\_1709

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Eric COSSEMENT et al. :  
Serial No. NEW : **Attn: APPLICATION BRANCH**  
Filed December 2, 2003 : Attorney Docket No. 2003-1709  
ENANTIOMERS OF 1-[(4-CHLOROPHENYL)  
PHENYLMETHYL]-4-[(4-METHYLPHENYL)  
SULFONYL]PIPERAZINE :  
(Rule 1.53(b) Continuation of Serial No.  
10/385,522, Filed March 12, 2003)

**CHANGE OF ADDRESS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

Sir:

*Effective **immediately***, please note the following change of  
address for the undersigned attorney of record:

**WENDEROTH, LIND & PONACK**

**2033 "K" Street, N.W.**


**Suite 800**

**Washington, D.C. 20006-1021**

Respectfully submitted,

Eric COSSEMENT et al.

By:

  
Michael R. Davis  
Registration No. 25,134 *for*  
John T. Miller  
Registration No. 21,120  
Attorney for Applicants

JTM/pth  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
December 2, 2003